These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

484 related items for PubMed ID: 15198739

  • 1. Response to desmopressin of factors XI, X and V in patients with factor VIII deficiency and von Willebrand disease.
    White B, Lawler P, Riddell A, Nitu-Whalley IC, Hermans C, Lee CA, Brown SA.
    Br J Haematol; 2004 Jul; 126(1):100-4. PubMed ID: 15198739
    [Abstract] [Full Text] [Related]

  • 2. Response of patients with hemophilia A and von Willebrand disease to desmopressin (DDAVP).
    Santiago-Borrero PJ, Casanova R.
    Bol Asoc Med P R; 1990 May; 82(5):207-10. PubMed ID: 2115785
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of high concentration intranasal and intravenous desmopressin in pediatric patients with mild hemophilia A or mild-to-moderate type 1 von Willebrand disease.
    Gill JC, Ottum M, Schwartz B.
    J Pediatr; 2002 May; 140(5):595-9. PubMed ID: 12032528
    [Abstract] [Full Text] [Related]

  • 4. [Von Willebrand disease: characteristics and response to desmopressin. Study of 103 cases].
    César JM, Avello AG, Vecino A, Cerveró C, Laraña JG, Fuertes IF, Villarrubia J, López J, de Oteyza JP, Velasco JL, Cantalapiedra A, Herrera P, Herrero S, Navarro JL.
    Med Clin (Barc); 1998 Nov 14; 111(16):601-3. PubMed ID: 9881332
    [Abstract] [Full Text] [Related]

  • 5. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A, Berneman Z, Schroyens W, Michiels JJ.
    Acta Haematol; 2009 Nov 14; 121(2-3):128-38. PubMed ID: 19506359
    [Abstract] [Full Text] [Related]

  • 6. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
    Favaloro EJ, Thom J, Patterson D, Just S, Dixon T, Koutts J, Baccala M, Rowell J, Baker R.
    Thromb Res; 2009 Apr 14; 123(6):862-8. PubMed ID: 19064279
    [Abstract] [Full Text] [Related]

  • 7. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K, Letowska M, Sabliński J, Binder BR, Kopeć M, Lopaciuk S.
    Acta Haematol Pol; 1994 Apr 14; 25(3):261-8. PubMed ID: 7992599
    [Abstract] [Full Text] [Related]

  • 8. Desmopressin: therapeutic limitations in children and adults with inherited coagulation disorders.
    Nolan B, White B, Smith J, O'Reily C, Fitzpatrick B, Smith OP.
    Br J Haematol; 2000 Jun 14; 109(4):865-9. PubMed ID: 10929043
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 14; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 11. Biologic response to subcutaneous and intranasal therapy with desmopressin in a large Amish kindred with Type 2M von Willebrand disease.
    Sharthkumar A, Greist A, Di Paola J, Winay J, Roberson C, Heiman M, Herbert S, Parameswaran R, Shapiro A.
    Haemophilia; 2008 May 14; 14(3):539-48. PubMed ID: 18312368
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization, classification, and treatment of von Willebrand diseases: a critical appraisal of the literature and personal experiences.
    Michiels JJ, Gadisseur A, Budde U, Berneman Z, van der Planken M, Schroyens W, van de Velde A, van Vliet H.
    Semin Thromb Hemost; 2005 Nov 14; 31(5):577-601. PubMed ID: 16276467
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A, Dannhauser D, Pontara E, Bertomoro A, Orazi B, Santarossa L, Zerbinati P, Girolami A.
    Blood Coagul Fibrinolysis; 1996 Jul 14; 7(5):549-53. PubMed ID: 8874865
    [Abstract] [Full Text] [Related]

  • 19. Laboratory response to intranasal desmopressin in women with menorrhagia and platelet dysfunction.
    Rose SS, Faiz A, Miller CH, Saidi P, Philipp CS.
    Haemophilia; 2008 May 14; 14(3):571-8. PubMed ID: 18312366
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.